These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 16955688

  • 21. 3-O-(3',3'-dimethysuccinyl) betulinic acid inhibits maturation of the human immunodeficiency virus type 1 Gag precursor assembled in vitro.
    Sakalian M, McMurtrey CP, Deeg FJ, Maloy CW, Li F, Wild CT, Salzwedel K.
    J Virol; 2006 Jun; 80(12):5716-22. PubMed ID: 16731910
    [Abstract] [Full Text] [Related]

  • 22. The 3-O-(3',3'-dimethylsuccinyl) derivative of betulinic acid (DSB) inhibits the assembly of virus-like particles in HIV-1 Gag precursor-expressing cells.
    DaFonseca S, Blommaert A, Coric P, Hong SS, Bouaziz S, Boulanger P.
    Antivir Ther; 2007 Jun; 12(8):1185-203. PubMed ID: 18240859
    [Abstract] [Full Text] [Related]

  • 23. Phase I evaluation of the safety, tolerability, and pharmacokinetics of GSK3640254, a next-generation HIV-1 maturation inhibitor.
    Joshi SR, Fernando D, Igwe S, McKenzie L, Krishnatry AS, Halliday F, Zhan J, Greene TJ, Xu J, Ferron-Brady G, Lataillade M, Min S.
    Pharmacol Res Perspect; 2020 Dec; 8(6):e00671. PubMed ID: 33200887
    [Abstract] [Full Text] [Related]

  • 24. Incorporation of Privileged Structures into Bevirimat Can Improve Activity against Wild-Type and Bevirimat-Resistant HIV-1.
    Zhao Y, Gu Q, Morris-Natschke SL, Chen CH, Lee KH.
    J Med Chem; 2016 Oct 13; 59(19):9262-9268. PubMed ID: 27676157
    [Abstract] [Full Text] [Related]

  • 25. Phase 1 clinical data on first-in-class HIV-1 maturation inhibitor, PA-457.
    S Afr Med J; 2004 Sep 13; 94(9):739. PubMed ID: 15487834
    [No Abstract] [Full Text] [Related]

  • 26. Identification and Characterization of BMS-955176, a Second-Generation HIV-1 Maturation Inhibitor with Improved Potency, Antiviral Spectrum, and Gag Polymorphic Coverage.
    Nowicka-Sans B, Protack T, Lin Z, Li Z, Zhang S, Sun Y, Samanta H, Terry B, Liu Z, Chen Y, Sin N, Sit SY, Swidorski JJ, Chen J, Venables BL, Healy M, Meanwell NA, Cockett M, Hanumegowda U, Regueiro-Ren A, Krystal M, Dicker IB.
    Antimicrob Agents Chemother; 2016 Jul 13; 60(7):3956-69. PubMed ID: 27090171
    [Abstract] [Full Text] [Related]

  • 27. Rilpivirine, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infection.
    Ripamonti D, Maggiolo F.
    Curr Opin Investig Drugs; 2008 Aug 13; 9(8):899-912. PubMed ID: 18666038
    [Abstract] [Full Text] [Related]

  • 28. A new assault on HIV.
    Stix G.
    Sci Am; 2006 Jun 13; 294(6):76-9. PubMed ID: 16711363
    [No Abstract] [Full Text] [Related]

  • 29. Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy/Liv mice.
    Stoddart CA, Joshi P, Sloan B, Bare JC, Smith PC, Allaway GP, Wild CT, Martin DE.
    PLoS One; 2007 Nov 28; 2(11):e1251. PubMed ID: 18043758
    [Abstract] [Full Text] [Related]

  • 30. An oral human drug absorption study to assess the impact of site of delivery on the bioavailability of bevirimat.
    Connor A, Evans P, Doto J, Ellis C, Martin DE.
    J Clin Pharmacol; 2009 May 28; 49(5):606-12. PubMed ID: 19304891
    [Abstract] [Full Text] [Related]

  • 31. PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing.
    Li F, Goila-Gaur R, Salzwedel K, Kilgore NR, Reddick M, Matallana C, Castillo A, Zoumplis D, Martin DE, Orenstein JM, Allaway GP, Freed EO, Wild CT.
    Proc Natl Acad Sci U S A; 2003 Nov 11; 100(23):13555-60. PubMed ID: 14573704
    [Abstract] [Full Text] [Related]

  • 32. Can the further clinical development of bevirimat be justified?
    Wainberg MA, Albert J.
    AIDS; 2010 Mar 13; 24(5):773-4. PubMed ID: 20154583
    [No Abstract] [Full Text] [Related]

  • 33. In vitro selection of clinically relevant bevirimat resistance mutations revealed by "deep" sequencing of serially passaged, quasispecies-containing recombinant HIV-1.
    Knapp DJ, Harrigan PR, Poon AF, Brumme ZL, Brockman M, Cheung PK.
    J Clin Microbiol; 2011 Jan 13; 49(1):201-8. PubMed ID: 21084518
    [Abstract] [Full Text] [Related]

  • 34. Polymorphisms in Gag spacer peptide 1 confer varying levels of resistance to the HIV- 1 maturation inhibitor bevirimat.
    Adamson CS, Sakalian M, Salzwedel K, Freed EO.
    Retrovirology; 2010 Apr 20; 7():36. PubMed ID: 20406463
    [Abstract] [Full Text] [Related]

  • 35. New betulinic acid derivatives for bevirimat-resistant human immunodeficiency virus type-1.
    Dang Z, Ho P, Zhu L, Qian K, Lee KH, Huang L, Chen CH.
    J Med Chem; 2013 Mar 14; 56(5):2029-37. PubMed ID: 23379607
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. PA-457, new kind of antiretroviral: ten-day clinical trial results.
    James JS.
    AIDS Treat News; 2005 Aug 26; (414):7-8. PubMed ID: 16206398
    [Abstract] [Full Text] [Related]

  • 38. Ibalizumab, a CD4-specific mAb to inhibit HIV-1 infection.
    Dimitrov A.
    Curr Opin Investig Drugs; 2007 Aug 26; 8(8):653-61. PubMed ID: 17668367
    [Abstract] [Full Text] [Related]

  • 39. Report from the 2008 joint ICAAC/IDSA meeting. Bevirimat: predictors of response.
    Sax PE.
    AIDS Clin Care; 2008 Dec 26; 20(12):104. PubMed ID: 19274775
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.